/IROGENETICS 
5. Geographical distribution: The TROVAC (FPpp) vector has the potential to 
be used as a vaccine for a wide variety of veterinary diseases world-wide. 
The highly attenuated phenotype of the TROVAC (FPpp) vector coupled to its 
potency as an immunization vehicle provides a favorable benefit-to-risk ratio. 
It possesses the physical characteristics desirable in a live vaccine candidate, 
i.e. genetic and environmental stability, yet has attenuation characteristics 
consistent with an enhanced safety profile. 
6. Recommended NIH/CDC Biosafety Level: The NIH/CDC recommended 
Biosafety Level for avipoxviruses is Biosafety Level 2. Avian pox is not of 
public health significance (Tripathy, 1991). The USDA has assigned BL1 and 
BL1-LS to our TROV AC-based NDV vaccine, vFP96, based upon their risk 
assessment of the current available information on the recombinant (Appendix 
K). Due to the attenuated nature of TROVAC (FPpp), the inherent host-range 
restriction of avipox viruses, and the safety data presented for both TROVAC 
(FPpp) and TROV AC-based recombinants, we are requesting reduction to 
Biosafety Level 1. 
Recombinant DNA Research, Volume 18 
[161] 
